Showing results (91-100 of 131) with videos related to

Sort By:
Pageof 14
Drugs - Real World Outcomes|June 6, 2023
Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) StudyKoichi Hirata, Mika Komori, Kaname Ueda, et al.
Annals of the New York Academy of Sciences|December 14, 2002
Genetic analysis of vascular factors in Alzheimer's diseaseYosuke Wakutani, Hisanori Kowa, Masayoshi Kusumi, et al.
Headache|October 16, 2019
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese AdultsFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.
Headache|June 21, 2021
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled studyTakao Takeshima, Fumihiko Sakai, Koichi Hirata, et al.
Headache|March 25, 2021
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraineFumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, et al.
Dementia and Geriatric Cognitive Disorders|January 24, 2004
The regulatory region polymorphisms of the MTHFR gene are not associated with Alzheimer's diseaseYosuke Wakutani, Hisanori Kowa, Masayoshi Kusumi, et al.
Pharmacoeconomics|May 21, 2024
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare PerspectiveTakao Takeshima, Fumihiko Sakai, Xinyu Wang, et al.
Brain Research|May 26, 2004
Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's diseaseKazuhiro Nakaso, Yuko Yoshimoto, Toshiya Nakano, et al.
The Journal of Headache and Pain|March 26, 2024
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trialMika Komori, Akichika Ozeki, Yuka Tanji, et al.
Expert Opinion on Drug Safety|December 29, 2022
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at homeKoichi Hirata, Takao Takeshima, Noboru Imai, et al.
Pageof 14